Bevacizumab plus irinotecan in patients with recurrent high grade malignant gliomas.

e13057 Background: Recurrent high grade malignant gliomas (MGs) have a short survival. Initial standard therapy is based on surgery followed by concurrent radiotherapy with Temozolomide (TMZ) and subsequent TMZ, however most patients relapse from their disease. On 2009, the FDA accelerated the approval of humanized IgG1 monoclonal antibody against VEGF bevacizumab as a single agent for patients (pts) with progressive MG following prior therapy, supported by durable objetive response rates. Further studies demonstrated an increased response rate (RR) and PFS with the addition of Irinotecan to Bevacizumab (I+B). Methods: We retrospectively analyzed 62 pts with recurrent MG treated in our hospital with Irinotecan plus Bevacizumab. Pts received Irinotecan 150 mg/m2 and Bevacizumab 10 mg/m2 every two weeks. Study endpoints were safety, RR and survival. Toxicity was scored according to NCI-CTC v4.0. Results: Sixty-two pts were included with a median 54 years old (range: 18-76). 75.8 % of them have the diagnosis...